Roche Presents Positive Clinical Data for Neurology Programs at EAN Annual Meeting

Retrieved on: 2021-06-22 13:06:57

Tags for this article:

Neurological disorders

Health

Clinical medicine

Autoimmune diseases

Monoclonal antibodies

Orphan drugs

Rare diseases

Multiple sclerosis

Neuromyelitis optica spectrum disorder

Ocrelizumab

Satralizumab

Spinal muscular atrophy

Click the tags to see associated articles and topics

Roche Presents Positive Clinical Data for Neurology Programs at EAN Annual Meeting. View article details on hiswai:

Excerpt

Here are some of the highlights: Roche's Sunfish trial studied risdiplam in patients with Type 2 or non-ambulatory Type 2 spinal muscular atrophy (SMA).

Article found on: www.biospace.com

View Original Article